Jaguar Health ( $JAGX): Rare-Disease Pivot and Regulatory Milestones Ahead (See the latest news for any ticker on Tickeron.) Rare-disease pivot is the core thesis: Jaguar Health has repositioned around crofelemer powder for oral solution as a potential treatment for rare intestinal failure conditions, with a New Drug Application (NDA) submission for microvillus inclusion disease (MVID) targeted for mid-2027. Near-term regulatory milestones: Management plans to apply for Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in Q4 2026, a step that could materially shape the regulatory timeline and investor sentiment. $FLNA $TCRT $MNOW $RNAZ